PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28679774-0	2017	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.	duocarmycin	16-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
29795377-0	2018	An anti-EGFR x cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.	duocarmycin	79-90	epidermal growth factor receptor	Homo sapiens	8-12
29795377-0	2018	An anti-EGFR x cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.	duocarmycin	79-90	epidermal growth factor receptor	Homo sapiens	110-114
29795377-0	2018	An anti-EGFR x cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.	duocarmycin	79-90	KRAS proto-oncogene, GTPase	Homo sapiens	142-146
29435172-0	2018	Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models.	duocarmycin	11-22	neural cell adhesion molecule 1	Homo sapiens	30-34
29435172-4	2018	Then, the promiximab was conjugated with a potent DNA alkylating agent duocarmycin via reduced interchain disulfides to yield the promiximab-Duocarmycin (promiximab-DUBA) conjugates.	duocarmycin	71-82	OTU deubiquitinase 5	Homo sapiens	165-169
29435172-4	2018	Then, the promiximab was conjugated with a potent DNA alkylating agent duocarmycin via reduced interchain disulfides to yield the promiximab-Duocarmycin (promiximab-DUBA) conjugates.	duocarmycin	141-152	OTU deubiquitinase 5	Homo sapiens	165-169
28679774-0	2017	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.	duocarmycin	16-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-146
28473206-0	2017	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.	duocarmycin	16-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
28947977-4	2017	It consists of a humanized endosialin monoclonal antibody, named hMP-E-8.3, conjugated to a potent duocarmycin derivative.	duocarmycin	99-110	CD248 molecule	Homo sapiens	27-37
28947977-4	2017	It consists of a humanized endosialin monoclonal antibody, named hMP-E-8.3, conjugated to a potent duocarmycin derivative.	duocarmycin	99-110	inner membrane mitochondrial protein	Homo sapiens	65-68
28473206-0	2017	SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.	duocarmycin	16-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	146-150
25844926-2	2015	CYP2W1 has been proposed as an attractive target for colorectal cancer (CRC) therapy by exploiting its ability to activate duocarmycin prodrugs to cytotoxic metabolites.	duocarmycin	123-134	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	0-6
25635711-0	2015	Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.	duocarmycin	44-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	86-90
28273004-4	2017	We analyzed the killing potential of TCR-like ADCs when cross-linked to the DNA alkylating compound duocarmycin.	duocarmycin	100-111	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	37-40
27256376-0	2016	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.	duocarmycin	16-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
27256376-0	2016	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.	duocarmycin	16-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	132-136
25869904-3	2016	BMS-936561 (alphaCD70_MED-A) is an antibody-drug conjugate composed of a fully human anti-CD70 monoclonal antibody (alphaCD70) conjugated with a duocarmycin derivative, MED-A, through a maleimide-containing citrulline-valine dipeptide linker.	duocarmycin	145-156	CD70 molecule	Homo sapiens	17-21
26373694-0	2015	Structural, Biochemical, and Computational Studies Reveal the Mechanism of Selective Aldehyde Dehydrogenase 1A1 Inhibition by Cytotoxic Duocarmycin Analogues.	duocarmycin	136-147	aldehyde dehydrogenase 1 family member A1	Homo sapiens	85-111
26373694-1	2015	Analogues of the natural product duocarmycin bearing an indole moiety were shown to bind aldehyde dehydrogenase 1A1 (ALDH1A1) in addition to DNA, while derivatives without the indole solely addressed the ALDH1A1 protein.	duocarmycin	33-44	aldehyde dehydrogenase 1 family member A1	Homo sapiens	89-115
26373694-1	2015	Analogues of the natural product duocarmycin bearing an indole moiety were shown to bind aldehyde dehydrogenase 1A1 (ALDH1A1) in addition to DNA, while derivatives without the indole solely addressed the ALDH1A1 protein.	duocarmycin	33-44	aldehyde dehydrogenase 1 family member A1	Homo sapiens	117-124
26373694-1	2015	Analogues of the natural product duocarmycin bearing an indole moiety were shown to bind aldehyde dehydrogenase 1A1 (ALDH1A1) in addition to DNA, while derivatives without the indole solely addressed the ALDH1A1 protein.	duocarmycin	33-44	aldehyde dehydrogenase 1 family member A1	Homo sapiens	204-211
26373694-2	2015	The molecular mechanism of selective ALDH1A1 inhibition by duocarmycin analogues was unraveled through cocrystallization, mutational studies, and molecular dynamics simulations.	duocarmycin	59-70	aldehyde dehydrogenase 1 family member A1	Homo sapiens	37-44
26373694-5	2015	The selectivity of duocarmycin analogues for ALDH1A1 is unique, since only minor alterations in the sequence of closely related protein isoforms restrict compound accessibility.	duocarmycin	19-30	aldehyde dehydrogenase 1 family member A1	Homo sapiens	45-52
25844926-9	2015	The imatinib mediated induction of CYP2W1 suggests an adjuvant therapy to treatment with duocarmycins that thus would involve induction of tumor CYP2W1 levels followed by the CYP2W1 activated duocarmycin prodrugs.	duocarmycin	89-100	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	35-41
25844926-9	2015	The imatinib mediated induction of CYP2W1 suggests an adjuvant therapy to treatment with duocarmycins that thus would involve induction of tumor CYP2W1 levels followed by the CYP2W1 activated duocarmycin prodrugs.	duocarmycin	89-100	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	145-151
25844926-9	2015	The imatinib mediated induction of CYP2W1 suggests an adjuvant therapy to treatment with duocarmycins that thus would involve induction of tumor CYP2W1 levels followed by the CYP2W1 activated duocarmycin prodrugs.	duocarmycin	89-100	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	145-151
25589493-0	2015	The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.	duocarmycin	31-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	49-53
25589493-0	2015	The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.	duocarmycin	31-42	erb-b2 receptor tyrosine kinase 2	Homo sapiens	112-116
25589493-1	2015	SYD985 is a HER2-targeting antibody-drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin payload.	duocarmycin	115-126	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
25589493-1	2015	SYD985 is a HER2-targeting antibody-drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin payload.	duocarmycin	115-126	OTU deubiquitinase 5	Homo sapiens	90-94
24625228-3	2014	CYP2W1 has proven to metabolize duocarmycin analogs into cytotoxic substances, compounds that in xenografts of CRC cells expressing CYP2W1 completely inhibit tumor growth.	duocarmycin	32-43	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	0-6
25189543-0	2014	Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.	duocarmycin	83-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-31
24625228-3	2014	CYP2W1 has proven to metabolize duocarmycin analogs into cytotoxic substances, compounds that in xenografts of CRC cells expressing CYP2W1 completely inhibit tumor growth.	duocarmycin	32-43	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	132-138
24088132-3	2013	Corresponding gene products (CYP2W1.1, CYP2W1.2 and CYP2W1.6) were expressed in human colon cancer SW480 cells and their activities towards two different substrates, the duocarmycin analogs ICT2706 and ICT2726, were monitored.	duocarmycin	170-181	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	29-35
24088132-3	2013	Corresponding gene products (CYP2W1.1, CYP2W1.2 and CYP2W1.6) were expressed in human colon cancer SW480 cells and their activities towards two different substrates, the duocarmycin analogs ICT2706 and ICT2726, were monitored.	duocarmycin	170-181	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	39-45
24088132-3	2013	Corresponding gene products (CYP2W1.1, CYP2W1.2 and CYP2W1.6) were expressed in human colon cancer SW480 cells and their activities towards two different substrates, the duocarmycin analogs ICT2706 and ICT2726, were monitored.	duocarmycin	170-181	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	39-45
23589180-0	2013	Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.	duocarmycin	51-62	cytochrome P450, family 2, subfamily w, polypeptide 1	Mus musculus	22-41
23844629-0	2013	Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.	duocarmycin	22-33	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	101-107
23844629-0	2013	Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.	duocarmycin	22-33	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	112-118
23844629-1	2013	A library of duocarmycin bioprecursors based on the CPI and CBI scaffolds was synthesized and used to probe selective activation by cells expressing CYP1A1 and 2W1, CYPs known to be expressed in high frequency in some tumors.	duocarmycin	13-24	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	149-163
23844629-3	2013	CYP2W1 was also shown to sensitize proliferating cells to several compounds, demonstrating its potential as a target for tumor selective activation of duocarmycin bioprecursors.	duocarmycin	151-162	cytochrome P450 family 2 subfamily W member 1	Homo sapiens	0-6
23589180-2	2013	Previously, we have identified duocarmycin synthetic derivatives as CYP2W1 substrates.	duocarmycin	31-42	cytochrome P450, family 2, subfamily w, polypeptide 1	Mus musculus	68-74
30620194-3	2019	Through in silico approaches, including principal component analysis, structure-similarity search, and docking calculations, protein tyrosine kinases, and especially the vascular endothelial growth factor receptor 2 (VEGFR-2), were predicted as targets of bifunctional duocarmycin analogues.	duocarmycin	269-280	kinase insert domain receptor	Homo sapiens	170-215
23033491-0	2013	Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.	duocarmycin	24-35	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	91-110
22002321-0	2011	Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.	duocarmycin	20-31	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	54-60
22002321-2	2011	Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analogue, ICT2700, which targets CYP1A1 for biological activity.	duocarmycin	75-86	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	120-126
12110316-0	2002	Novel furano analogues of duocarmycin C1 and C2: design, synthesis, and biological evaluation of seco-iso-cyclopropylfurano[2,3-e]indoline (seco-iso-CFI) and seco-cyclopropyltetrahydrofurano[2,3-f]quinoline (seco-CFQ) analogues.	duocarmycin	26-37	complement component factor i	Mus musculus	149-152
9875290-0	1998	The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin.	duocarmycin	227-238	tumor protein p53	Homo sapiens	25-28
9875290-6	1998	We found that DU-86, a duocarmycin derivative which alkylates DNA, bound ssDNA and enhanced the DNA binding activity of the p53 C-terminus.	duocarmycin	23-34	tumor protein p53	Homo sapiens	124-127
30292795-0	2019	Bispecific anti-mPDGFRbeta x cotinine scFv-Ckappa-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRbeta expressing cells.	duocarmycin	83-94	platelet derived growth factor receptor, beta polypeptide	Mus musculus	16-26
30292795-0	2019	Bispecific anti-mPDGFRbeta x cotinine scFv-Ckappa-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRbeta expressing cells.	duocarmycin	83-94	platelet derived growth factor receptor, beta polypeptide	Mus musculus	175-185
30292795-2	2019	In this study, we observed that a bispecific anti-murine platelet-derived growth factor receptor beta (mPDGFRbeta) x cotinine single-chain variable fragment (scFv)-kappa constant region (Ckappa)-scFv fusion protein and cotinine-duocarmycin can form an ADC-like complex to induce cytotoxicity against mPDGFRbeta expressing cells.	duocarmycin	228-239	platelet derived growth factor receptor, beta polypeptide	Mus musculus	103-113
30292795-2	2019	In this study, we observed that a bispecific anti-murine platelet-derived growth factor receptor beta (mPDGFRbeta) x cotinine single-chain variable fragment (scFv)-kappa constant region (Ckappa)-scFv fusion protein and cotinine-duocarmycin can form an ADC-like complex to induce cytotoxicity against mPDGFRbeta expressing cells.	duocarmycin	228-239	immunglobulin heavy chain variable region	Homo sapiens	158-162
30292795-2	2019	In this study, we observed that a bispecific anti-murine platelet-derived growth factor receptor beta (mPDGFRbeta) x cotinine single-chain variable fragment (scFv)-kappa constant region (Ckappa)-scFv fusion protein and cotinine-duocarmycin can form an ADC-like complex to induce cytotoxicity against mPDGFRbeta expressing cells.	duocarmycin	228-239	immunglobulin heavy chain variable region	Homo sapiens	195-199
14696094-3	2004	Stable transfectants of hnRNP L showed high sensitivity of the cells to the growth inhibitory effect of KW-2189, a duocarmycin derivative in vitro.	duocarmycin	115-126	heterogeneous nuclear ribonucleoprotein L	Homo sapiens	24-31
10554008-2	1999	We have used gel mobility shift assays to detect proteins that bind to DNA treated in vitro with duocarmycin SA and identified a protein, named duocarmycin-DNA adduct recognizing protein (DARP), which binds with increased affinity to duocarmycin-damaged DNA.	duocarmycin	97-108	ankyrin repeat domain 23	Homo sapiens	144-186
10554008-2	1999	We have used gel mobility shift assays to detect proteins that bind to DNA treated in vitro with duocarmycin SA and identified a protein, named duocarmycin-DNA adduct recognizing protein (DARP), which binds with increased affinity to duocarmycin-damaged DNA.	duocarmycin	97-108	ankyrin repeat domain 23	Homo sapiens	188-192
30620194-3	2019	Through in silico approaches, including principal component analysis, structure-similarity search, and docking calculations, protein tyrosine kinases, and especially the vascular endothelial growth factor receptor 2 (VEGFR-2), were predicted as targets of bifunctional duocarmycin analogues.	duocarmycin	269-280	kinase insert domain receptor	Homo sapiens	217-224
30620194-7	2019	In vitro assays revealed this bifunctional duocarmycin analogue as a strong inhibitor of VEGFR-2, with low residual aldehyde dehydrogenase 1 activity.	duocarmycin	43-54	kinase insert domain receptor	Homo sapiens	89-96
30620194-8	2019	Altogether, studies revealed bifunctional duocarmycin analogues as a new class of naturally derived compounds that express a very high cytotoxicity to cancer cells overexpressing aldehyde dehydrogenase 1 as well as VEGFR-2.	duocarmycin	42-53	kinase insert domain receptor	Homo sapiens	215-222